JP2008531594A - 酒石酸ラドスチジルの製剤 - Google Patents

酒石酸ラドスチジルの製剤 Download PDF

Info

Publication number
JP2008531594A
JP2008531594A JP2007557195A JP2007557195A JP2008531594A JP 2008531594 A JP2008531594 A JP 2008531594A JP 2007557195 A JP2007557195 A JP 2007557195A JP 2007557195 A JP2007557195 A JP 2007557195A JP 2008531594 A JP2008531594 A JP 2008531594A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weight
amount
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007557195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531594A5 (enExample
Inventor
リチト、ダニエラ
ロビンゲル、イオアナ
カシウラル、ファンニー
ギルベルト、アドリアン
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2008531594A publication Critical patent/JP2008531594A/ja
Publication of JP2008531594A5 publication Critical patent/JP2008531594A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007557195A 2005-02-24 2006-02-24 酒石酸ラドスチジルの製剤 Withdrawn JP2008531594A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65647705P 2005-02-24 2005-02-24
PCT/US2006/006636 WO2006091836A1 (en) 2005-02-24 2006-02-24 Formulations of ladostigil tartrate

Publications (2)

Publication Number Publication Date
JP2008531594A true JP2008531594A (ja) 2008-08-14
JP2008531594A5 JP2008531594A5 (enExample) 2009-03-05

Family

ID=36927766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557195A Withdrawn JP2008531594A (ja) 2005-02-24 2006-02-24 酒石酸ラドスチジルの製剤

Country Status (7)

Country Link
US (2) US8022104B2 (enExample)
EP (1) EP1848417A1 (enExample)
JP (1) JP2008531594A (enExample)
AU (1) AU2006216509B8 (enExample)
CA (1) CA2600603A1 (enExample)
IL (1) IL185420A0 (enExample)
WO (1) WO2006091836A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2600603A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Formulations of ladostigil tartrate
WO2007038677A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Methods for preparation of ladostigil tartrate crystalline form a1
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691A1 (en) * 2006-03-31 2007-10-04 Tamar Goren Use of ladostigil for the treatment of schizophrenia
WO2012059920A1 (en) * 2010-11-02 2012-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigil dosage regime
EP2811995B1 (en) 2012-02-12 2017-08-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Ladostigil therapy for immunomodulation
WO2013182625A1 (en) * 2012-06-08 2013-12-12 Actavis Group Ptc Ehf Pharmaceutical formulation with propargylamine compound

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1534864A (en) * 1919-12-19 1925-04-21 Hazel Atlas Glass Co Apparatus for tempering glassware
US2026165A (en) * 1934-08-01 1935-12-31 Libbey Owens Ford Glass Co Process and apparatus for producing case hardened glass
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4086263A (en) * 1976-11-17 1978-04-25 Ppg Industries, Inc. Shipping rack having spacer strips attached thereto
US4488192A (en) * 1982-05-28 1984-12-11 International Business Machines Corporation Cooling arrangement for hermetically sealed disk files
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
AU1867095A (en) 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
FI100397B (fi) * 1995-10-24 1997-11-28 Glassrobots Oy Lämmönsiirtomenetelmä lasilevyjen taivutusuunissa ja taivutusuuni
US6053011A (en) * 1996-03-21 2000-04-25 Lisec; Peter Process and plant for hardening glass plates
FR2747112B1 (fr) * 1996-04-03 1998-05-07 Commissariat Energie Atomique Dispositif de transport d'objets plats et procede de transfert de ces objets entre ledit dispositif et une machine de traitement
DE69725467T2 (de) 1996-12-18 2004-07-22 Teva Pharmaceutical Industries Ltd. Phenylethylamin-derivate
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
DE69732984T2 (de) 1996-12-18 2006-02-16 Teva Pharmaceutical Industries Ltd. Aminoindanderivate
CA2276150A1 (en) 1996-12-30 1998-07-09 Steven D. Young Inhibitors of farnesyl-protein transferase
JPH1179388A (ja) * 1997-09-16 1999-03-23 Mitsui Eng & Shipbuild Co Ltd ガラス類枚葉処理装置
JPH1179389A (ja) * 1997-09-16 1999-03-23 Mitsui Eng & Shipbuild Co Ltd 基板ガラス検査加工システム
TW444275B (en) * 1998-01-13 2001-07-01 Toshiba Corp Processing device, laser annealing device, laser annealing method, manufacturing device and substrate manufacturing device for panel display
CA2477218A1 (en) 2002-02-27 2003-09-04 Teva Pharmaceutical Industries, Ltd. Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
US20040010038A1 (en) 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
EP1686973A4 (en) 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
US20050267076A1 (en) 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function
CA2600603A1 (en) 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Formulations of ladostigil tartrate
EP1848689A1 (en) 2005-02-24 2007-10-31 Teva Pharmaceutical Industries Ltd. Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
US20060276537A1 (en) 2005-06-01 2006-12-07 Tamar Goren Use of ladostigil for the treatment of multiple sclerosis
EP1956904B1 (en) 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Low-dose ladostigil for the treatment of mild cognitive impairment
US20070135518A1 (en) 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691A1 (en) 2006-03-31 2007-10-04 Tamar Goren Use of ladostigil for the treatment of schizophrenia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521402A (ja) * 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用

Also Published As

Publication number Publication date
WO2006091836A9 (en) 2006-10-26
US20060189685A1 (en) 2006-08-24
US20110301234A1 (en) 2011-12-08
WO2006091836A1 (en) 2006-08-31
WO2006091836A8 (en) 2007-04-12
EP1848417A1 (en) 2007-10-31
US8022104B2 (en) 2011-09-20
IL185420A0 (en) 2008-08-07
AU2006216509A1 (en) 2006-08-31
CA2600603A1 (en) 2006-08-31
AU2006216509B8 (en) 2012-11-01
AU2006216509B2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
US11998639B2 (en) Formulations of (R)-2-amino-3-phenylpropyl carbamate
US20110301234A1 (en) Formulations of ladostigil tartrate
US11717498B2 (en) Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
IL224230A (en) Compositions containing nalbupines and their uses
US20230157947A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
KR20010034703A (ko) 플루옥세틴과 이의 거울상이성질체의 안정한 약형
US20250032442A1 (en) Methods and compositions for treating cognitive impairment
US20070172521A1 (en) Levetiracetam formulations and methods for their manufacture
EP3431078B1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions
TWI299333B (en) Crystalline forms of 1,24(s)-dihydroxy vitamin d2
US20060257475A1 (en) Stable Sertraline Hydrochloride Formulation and Method
EP4604942A1 (en) Content uniformity of teriflunomid in pharmaceutical dosage forms
CN109939239B (zh) 药物组合物及其制备方法
JPS60202812A (ja) ブロモクリプチン組成物
US20250213502A1 (en) Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms
EP4536191A1 (en) Ebselen containing oral dosage forms
EP2996681B1 (en) Pharmaceutical composition comprising fingolimod
TR2025004415T2 (tr) İçeri̇k tekdüzeli̇ği̇ sağlanmiş teri̇flunomi̇d farmasöti̇k dozaj formlari
WO2017114597A1 (en) Pharmaceutical dosage forms comprising ((cis)-n-(4-(dimethylamino)-1,4- diphenylcyclohexyl)-n-methylcinnamamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090115

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090122